Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1954 1
1956 1
1957 1
1958 2
1959 2
1961 4
1962 2
1965 1
1967 1
1968 4
1969 4
1970 3
1971 2
1972 1
1973 1
1974 2
1975 3
1978 1
1980 1
1983 1
1986 1
1988 2
1989 1
1992 1
1996 3
1997 2
1998 1
1999 1
2000 3
2001 3
2002 2
2004 7
2005 5
2006 4
2007 2
2008 1
2009 2
2010 6
2011 1
2013 2
2015 2
2016 2
2017 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Results by year

Filters applied: . Clear all
Page 1
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.
Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. Weisberg E, et al. Among authors: mestan j. Br J Cancer. 2006 Jun 19;94(12):1765-9. doi: 10.1038/sj.bjc.6603170. Epub 2006 May 23. Br J Cancer. 2006. PMID: 16721371 Free PMC article. Review.
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O'Reilly T, Traxler P, Chaudhuri B, Fretz H, Zimmermann J, Meyer T, Caravatti G, Furet P, Manley PW. Fabbro D, et al. Among authors: mestan j. Pharmacol Ther. 2002 Feb-Mar;93(2-3):79-98. doi: 10.1016/s0163-7258(02)00179-1. Pharmacol Ther. 2002. PMID: 12191602 Review.
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Adrián FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, Zhang G, Hur W, Ding S, Manley P, Mestan J, Fabbro D, Gray NS. Adrián FJ, et al. Among authors: mestan j. Nat Chem Biol. 2006 Feb;2(2):95-102. doi: 10.1038/nchembio760. Epub 2006 Jan 15. Nat Chem Biol. 2006. PMID: 16415863
A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis.
Bold G, Schnell C, Furet P, McSheehy P, Brüggen J, Mestan J, Manley PW, Drückes P, Burglin M, Dürler U, Loretan J, Reuter R, Wartmann M, Theuer A, Bauer-Probst B, Martiny-Baron G, Allegrini P, Goepfert A, Wood J, Littlewood-Evans A. Bold G, et al. Among authors: mestan j. J Med Chem. 2016 Jan 14;59(1):132-46. doi: 10.1021/acs.jmedchem.5b01582. Epub 2015 Dec 21. J Med Chem. 2016. PMID: 26629594
90 results